CancerNCT06307496

VIDeOS for Smoking Cessation

A study testing Smoking cessation intervention and Informational intervention in people with Cancer and Smoking Cessation, run by Medical University of South Carolina at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Cancer, Smoking Cessation
What is being tested?: Smoking cessation intervention and Informational intervention
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 40 participants
Where: 1 siteUnited States
Study dates: 24 Sep 2024to 10 Sep 2025
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age 18 or older
Diagnosed with cancer (any type)
Receiving care at Medical University of South Carolina
Reads and understands English language
Currently smoking cigarettes (any amount)

Who cannot join

Unstable or poorly managed medical or psychiatric conditions that impair cognition and ability to provide informed consent (e.g., dementia, active psychosis).

Trial locations and contacts

1 site in 1 country.

United States1 site

Medical University of South Carolina
Charleston, South Carolina, 29425

Other trials in United States

About this study

Official title: Video Interventions for Dependence On Smoking (VIDeOS) for Cancer Patients: A Randomized Controlled Pilot Study

The purpose of the current study is to pilot the efficacy, feasibility, and acceptability of an evidence-based smoking cessation intervention adapted for cancer patients and delivered via video. Investigators aim to assess if this intervention is considered acceptable by participants, feasible to implement, and effective at increasing knowledge about smoking cessation before conducting a fully powered clinical trial.

Read the detailed description

A randomized controlled pilot study is being conducted to test the acceptability and feasibility of a smoking cessation intervention tailored for cancer patients that is delivered via video. Participants will be in a video intervention or control group that receives information about quitting smoking. Participants will complete surveys prior to randomization, and will complete additional surveys one week, one month, and three months post-randomization to provide their thoughts about the videos, information about changes to smoking behaviors, and knowledge about quitting smoking.

Conditions: Cancer, Smoking Cessation
Being tested: Smoking cessation intervention, Informational intervention
Keywords: Videos
Medical subject headings: Neoplasms, Smoking Cessation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Smoking cessation interventionOther
Receive links to smoking cessation videos
Informational interventionOther
Receive NCI's "Clearing the Air" booklet

Study groups in NCT06307496
Study group	Role	What they receive
Videos	Experimental	Participants will be sent links to smoking cessation videos to watch. Receives: Other: Smoking cessation intervention
NCI Pamphlet	Active comparator	Participants will be sent links to NCI's "Clearing the Air" to read. Receives: Other: Informational intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

Acceptability of Intervention Measure
Acceptability will be measured using the measure titled the "Acceptability of Intervention Measure" (AIM), which contains four items with answer options on a scale from 1-5. Higher scores indicating higher acceptability. We will consider the intervention "acceptable" if an average score of 4 or higher is obtained.
Measured: 1 week post-randomization
Feasibility of Intervention Measure
Feasibility will be measured using the measure title the "Feasibility of Intervention Measure" (FIM), which contains four items with answer options on a scale from 1-5. Answer responses are summed and averaged. Higher scores indicating higher feasibility. We will consider the intervention "feasible" if an average score of 4 or higher is obtained.
Measured: 1 week post-randomization
Number of Participants Retained
We will determine if there are differences in retention rates between intervention groups.
Measured: 1 week, 1 month, and 3 months post-randomization

Secondary outcomes (2)

Number of Questions About Knowledge Related to Quitting Smoking That Were Answered Correctly
Questions about the impact of quitting smoking were asked to determine if there were numeric differences in the number of participants who answered each question correctly between intervention and control groups at 1-week follow-ups. Questions were true or false questions generated by the primary investigator. We calculated the number of participants who answered each of the three questions correctly.
Measured: 1 week
Number of Participants Who Made Quit Attempts and Achieved Smoking Abstinence at 1-week, 1-month, and 3-month Follow-ups
We calculated the number of 24-hour quit attempts made by participants in each group at the 1-week, 3-month, and 6-month follow-ups. We also calculated the number of participants who reported past 7-day point prevalence abstinence at 1-week, 1-month, and 3-month follow-ups.
Measured: 1 week, 1 month, and 3 months post-randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

24 Sep 202410 Sep 2025

First posted12 Mar 2024
Study start24 Sep 2024
Primary completion10 Sep 2025
Study completion10 Sep 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for CancerStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 40 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06307496
Sponsor's protocol ID: Pro00133913
Status last verified: Sep 2026
First submitted: 5 Mar 2024
Last updated: 29 Sep 2026
Results posted: Yes, on ClinicalTrials.gov
FDA-regulated drug: No
FDA-regulated device: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Not yet recruitingPhase 2
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
Cachexia-Anorexia Syndrome, Cachexia; Cancer
RecruitingPhase 2
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Esophageal Squamous Cell Carcinoma, Immunotherapy
Not yet recruitingPhase 1/2
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

All Cancer trials

Study at a glance

From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Video Interventions for Dependence On Smoking (VIDeOS) for Cancer Patients: A Randomized Controlled Pilot Study
ClinicalTrials.gov ID: NCT06307496
Acronym / sponsor ID: Pro00133913
Conditions: Cancer, Smoking Cessation
Keywords: Videos
Study type: Interventional
Recruitment status: Completed
Enrolment: 40 participants (actual)
Lead sponsor: Medical University of South CarolinaUniversity, hospital or other
Collaborators: National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology
Study start: 24 Sep 2024 (actual)
Primary completion: 10 Sep 2025 (actual)
Study completion: 10 Sep 2025 (actual)
First posted: 12 Mar 2024 (actual)
Results: Posted 29 Sep 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Other
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Videos	Experimental	Other: Smoking cessation interventionParticipants will be sent links to smoking cessation videos to watch.
NCI Pamphlet	Active comparator	Other: Informational interventionParticipants will be sent links to NCI's "Clearing the Air" to read.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Age 18 or older
Diagnosed with cancer (any type)
Receiving care at Medical University of South Carolina
Reads and understands English language
Currently smoking cigarettes (any amount)

Key exclusion criteria (1 listed)

Unstable or poorly managed medical or psychiatric conditions that impair cognition and ability to provide informed consent (e.g., dementia, active psychosis).

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Smoking cessation interventionReceive links to smoking cessation videos	Other	Videos
Informational interventionReceive NCI's "Clearing the Air" booklet	Other	NCI Pamphlet

Primary outcome

Acceptability of Intervention Measure
Time frame: 1 week post-randomization
Acceptability will be measured using the measure titled the "Acceptability of Intervention Measure" (AIM), which contains four items with answer options on a scale from 1-5. Higher scores indicating higher acceptability. We will consider the intervention "acceptable" if an average score of 4 or higher is obtained.
Feasibility of Intervention Measure
Time frame: 1 week post-randomization
Feasibility will be measured using the measure title the "Feasibility of Intervention Measure" (FIM), which contains four items with answer options on a scale from 1-5. Answer responses are summed and averaged. Higher scores indicating higher feasibility. We will consider the intervention "feasible" if an average score of 4 or higher is obtained.
Number of Participants Retained
Time frame: 1 week, 1 month, and 3 months post-randomization
We will determine if there are differences in retention rates between intervention groups.

2 secondary outcomes

Number of Questions About Knowledge Related to Quitting Smoking That Were Answered Correctly
Time frame: 1 week
Number of Participants Who Made Quit Attempts and Achieved Smoking Abstinence at 1-week, 1-month, and 3-month Follow-ups
Time frame: 1 week, 1 month, and 3 months post-randomization

Results and safety

Results posted to the registry on 29 Sep 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Videos	20	20
NCI Pamphlet	20	20

Primary outcome: Acceptability of Intervention Measure

Time frame: 1 week post-randomization. Mean (Standard Deviation). Unit: score on a scale

Measure	Videos n = 18	NCI Pamphlet n = 16
Value	4.2 (0.54)	3.9 (0.52)

Primary outcome: Feasibility of Intervention Measure

Time frame: 1 week post-randomization. Mean (Standard Deviation). Unit: score on a scale

Measure	Videos n = 18	NCI Pamphlet n = 16
Value	4.0 (0.53)	3.8 (0.45)

Primary outcome: Number of Participants Retained

Time frame: 1 week, 1 month, and 3 months post-randomization. Number. Unit: participants

Measure	Videos n = 20	NCI Pamphlet n = 20
1-week retention	18	16
1-month retention	14	12
3-months retention	15	12

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: Adverse events were not collected given the study was a low-risk behavioral intervention study assessing acceptability and feasibility of using video for smoking cessation.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Videos	0 of 0	0 of 0	0
NCI Pamphlet	0 of 0	0 of 0	0

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Cancer

Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Not yet recruitingPhase 2
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
Cachexia-Anorexia Syndrome, Cachexia; Cancer
RecruitingPhase 2
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Esophageal Squamous Cell Carcinoma, Immunotherapy
Not yet recruitingPhase 1/2
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Smoking cessation intervention and Informational intervention in people with Cancer and Smoking Cessation, run by Medical University of South Carolina at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Sep 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Acceptability of Intervention Measure (time frame: 1 week post-randomization). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06307496.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.